Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.

"Declarations Conflicts of interestThe research activities of RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel) are supported by the University Hospital and the University of Basel and by grants from Novartis, Roche and Neurostatus-UHB AG. One of the main projects of RC2NB is the development of a new comprehensive MS Digital solution. This study was performed in collaboration with Healios AG, Basel, Switzerland and received funding from the Swiss Innovation Agency (Innosuisse, project ID 33535.1 IP-ICT). PopReach Incorporated (Peak) provided access to selected cognitive training games without any influence on the study design, analysis, and interpretation. Silvan Pless has nothing to disclose. Tim Woelfle has nothing to disclose. Yvonne Naegelin’s institution (University Hospital Basel) has received financial support for lectures from Teva and Celgene and grant support from Innosuisse (Swiss Innovation Agency). Johannes Lorscheider’s institution has received research grants from Novartis, Biogen and Innosuisse as well as honoraria for advisory boards and/or speaking fees from Novartis, Roche and Teva. Oscar Reyes is Lead Data Scientist of Healios AG. Andrea Wiencierz has nothing to disclose. Pasquale Calabrese has received honoraria for speaking at scientific meetings, serving at scientific advisory boards and consulting activities from: Abbvie, Actelion, Almirall, Bayer-Schering, Biogen Idec, Celgene, EISAI, Genzyme, Lundbeck, Merck Serono, Novartis, Pfizer, Teva, and Sanofi-Aventis. His research is also supported by the Swiss Multiple Sclerosis Society and the Swiss National Research Foundation. Ludwig Kappos has received no personal compensation. His institution (University Hospital Basel/Foundation Clinical Neuroimmunology and Neuroscience Basel) has received the following exclusively for research support: steering committee, advisory board and consultancy fees (Abbvie, Actelion, AurigaVision AG, Biogen, Celgene, Desitin, Eli Lilly, EMD Serono, Genentech, Genzyme, Glaxo Smith Kline, Janssen, Japan Tobacco, Merck, Minoryx, Novartis, Roche, Sanofi, Santhera, Senda, Shionogi, Teva, and Wellmera; speaker fees (Celgene, Janssen, Merck, Novartis, and Roche); support for educational activities (Biogen, Desitin, Novartis, Sanofi and Teva); license fees for Neurostatus products; and grants (European Union, Innosuisse, Novartis, Roche Research Foundation, Swiss MS Society and Swiss National Research Foundation). Conflicts of interest The research activities of RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel) are supported by the University Hospital and the University of Basel and by grants from Novartis, Roche and Neurostatus-UHB AG. One of the main projects of RC2NB is the development of a new comprehensive MS Digital solution. This study was performed in collaboration with Healios AG, Basel, Switzerland and received funding from the Swiss Innovation Agency (Innosuisse, project ID 33535.1 IP-ICT). PopReach Incorporated (Peak) provided access to selected cognitive training games without any influence on the study design, analysis, and interpretation. Silvan Pless has nothing to disclose. Tim Woelfle has nothing to disclose. Yvonne Naegelin’s institution (University Hospital Basel) has received financial support for lectures from Teva and Celgene and grant support from Innosuisse (Swiss Innovation Agency). Johannes Lorscheider’s institution has received research grants from Novartis, Biogen and Innosuisse as well as honoraria for advisory boards and/or speaking fees from Novartis, Roche and Teva. Oscar Reyes is Lead Data Scientist of Healios AG. Andrea Wiencierz has nothing to disclose. Pasquale Calabrese has received honoraria for speaking at scientific meetings, serving at scientific advisory boards and consulting activities from: Abbvie, Actelion, Almirall, Bayer-Schering, Biogen Idec, Celgene, EISAI, Genzyme, Lundbeck, Merck Serono, Novartis, Pfizer, Teva, and Sanofi-Aventis. His research is also supported by the Swiss Multiple Sclerosis Society and the Swiss National Research Foundation. Ludwig Kappos has received no personal compensation. His institution (University Hospital Basel/Foundation Clinical Neuroimmunology and Neuroscience Basel) has received the following exclusively for research support: steering committee, advisory board and consultancy fees (Abbvie, Actelion, AurigaVision AG, Biogen, Celgene, Desitin, Eli Lilly, EMD Serono, Genentech, Genzyme, Glaxo Smith Kline, Janssen, Japan Tobacco, Merck, Minoryx, Novartis, Roche, Sanofi, Santhera, Senda, Shionogi, Teva, and Wellmera; speaker fees (Celgene, Janssen, Merck, Novartis, and Roche); support for educational activities (Biogen, Desitin, Novartis, Sanofi and Teva); license fees for Neurostatus products; and grants (European Union, Innosuisse, Novartis, Roche Research Foundation, Swiss MS Society and Swiss National Research Foundation)."

"Funding Open access funding provided by University of Basel. This study was performed in collaboration with Healios AG, Basel, Switzerland and received funding from the Swiss Innovation Agency (Innosuisse, project ID 33535.1 IP-ICT)."